Hematopoietic and bone marrow stem cells are top cells used in stem cell therapy accounting 36% and 34% of total studies, respectively followed by neural stem cells (14%, mesenchymal stem cells (11%), adipose derived stem cells (4%) and embryonic stem cells (1%) as shown in Figure 2 .
A tremendous growth has been observed in last decade in stem cell research especially MSCs, with a ratio of 100% increase as shown in Figure 3 . Being dramatic increase in stem cell research, challenges faced by researchers have been reduced and improved efficiency has been observed with every passed year [5] . A number of challenges are still faced by the researchers like clinical grade stem cells production, teratomic behaviour, escape of grafted cells, possible microbial contaminations etc. [6, 7] as shown in Figure 4 . It can also be said that unfortunately stem cell researchers are unaware of cGMP protocol. 
Clinical Grade Production of Stem Cells and cGMP Protocol:
First step for clinical grade production is testing their regenerative potential as pre-clinical studies on animal models such as rats, porcine, monkey, etc. 
Establishment of Stem Cell Commercialization Organizations:
To commercialize/transform stem cell research or to transform stem cell research into health industry, a number of proposals are given by different stem cell scientists who explained the strategies to implement research into clinics [10] . Commercialization organization should bridge the gap between researchers and doctors to commercialize therapeutic researchers. Cell therapy is a type of advanced therapeutic medicinal products (ATMPs) which must comply with current good manufacturing practice (cGMP) before applications which require a huge capital investment and expertise in skills. Pharmaceutical companies are the best examples of organizations who can commercialize stem cell research as they are well Commercialization of cell therapeutic research should maintain a strong pipeline, along with a planned growth of intellectual property (IP). Following three steps should be followed by an organization working for the commercialization of therapeutic sciences; (1) Measuring effectiveness in pre-clinical trials in appropriate animal models. To gain money for advanced production of cell therapeutic products, one strategy is obtaining allowance of easy-to-produce and low cost products (as first-line treatment option), partner or obtain financing for manufacture, sales, and distribution of this first product; and concurrently advance the second-line treatment option (products need pass through clinical trials) with further investment rounds and revenues. The first easy-to-produce medical goods can financially guarantee advance forward the production of high-cost second-line product.
Business Perspectives:
Transformation of research into clinical practice requires forging of strong coordination among organizations such as universities, hospitals, patient associations etc. Most important organizations are biotech and pharmaceutical industries. Along with huge investment, these firms need huge moral and ethical supports for clinical commercialization. Ethical authorities should support companies after a complicated review process of their innovations and patents in clinical researches starting from the basic research to registration. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that product candidates th year because of the low growth in first 3-4 years. To maintain company profit flow, following options can be considered. (1) Grants by public and private institutes, (2) by outsourcing, and/or (3) by collaborations with university partners and other joint venture partners to enhance competitive edge providing expertise, technical facilities and special needs, and ultimately, manufacturing, testing and commercialization support.
Conclusion:
The gap among researchers, policy makers, ethical regulation authorities and industry experts is the main reason of failure to gain patient-doctor confidence and to commercialize stem cell research. Stem cell research is gaining a huge attention by researchers worldwide but it is failed to get popularity among medical practitioners to start clinical trials and to start cell therapy in their routine clinical practice. Absence of local regulatory authorities to monitor and approve stem cell research is also a major challenging task in stem cell commercialization. In a number of states and regions of the world, stem cell regulating authorities are composed of medical practitioners and policy makers who have little or no information on regarding stem cell biology. A very strong communication system and multidisciplinary efforts are required to get stem cell research from laboratory to health sector. 
